Novo Nordisk CEO to face off with Bernie Sanders over 1,300% Ozempic markup in U.S.

Lars Fruergaard Jorgensen, chief executive officer of Novo Nordisk A/S, gestures while speaking during a Bloomberg Television interview in London, U.K. (Credit: Chris Ratcliffe—Bloomberg/Getty Images)

Novo Nordisk was the company of 2023, soaring to the mantle of Europe’s most valuable company as its bumper weight-loss-aiding drug Ozempic flew off pharmacy shelves and shaved several inches off consumers’ waistlines. That is, provided its U.S. customers could first cough up the exorbitant price.

Now, Novo Nordisk CEO Lars Fruergaard Jørgensen has volunteered to testify to the U.S. Senate to defend the massive markup Americans pay compared to Brits and Europeans.